RAYMOND TAETLE, M.D.
Osteopathic Medicine at Wilmot Rd, Tucson, AZ

5667781, Sep 16, 1997

Sep 30, 1991

7/767786

Ian S. Trowbridge - San Diego CA
Raymond Taetle - Tucson AZ
Suhaila N. White - Poway CA

The Salk Institute for Biological Studies - San Diego CA
The Regents of the University of California - Oakland CA

A61K 39395

4241431

Combinations of monoclonal antibodies which are highly effective for inhibiting cell growth and methods for inhibiting cell growth employing novel combinations of monoclonal antibodies are disclosed. The antibodies employed are capable of binding to the human transferrin receptor glycoprotein and, in combination, usually exhibit a substantially greater inhibition of cell growth than either of the antibodies individually when administered in comparable amounts, e. g. at saturation conditions. In preferred combinations, at least one member of the combination is individually highly effective to inhibit cell growth and at least one other member of the combination is individually substantially ineffective to inhibit cell growth. Combinations are selected based upon an in vitro screening test using CCRF-CEM cells which express the human Tf receptor.

5563176, Oct 8, 1996

Jul 15, 1994

8/276169

Michael J. Kelner - La Jolla CA
Trevor C. McMorris - La Jolla CA
Raymond Taetle - Tucson AZ

The Regents of the University of California - Oakland CA

A61K 3112, C07C 49403

514691

Antineoplastic illudin analogs are provided of the formula: wherein R. sub. 4, R. sub. 5 and R. sub. 6 are (C. sub. 1 -C. sub. 4)alkyl, Y is H, (C. sub. 1 -C. sub. 3)alkyl, (R. sub. 4)R. sub. 5)(R. sub. 6)Si or alkanoyl ((C. sub. 1 -C. sub. 4)alkylC(O)) and R is CH. sub. 2 OH, halo, benzyl optionally substituted with OY, or alkanoylmethyl (CH. sub. 2 OC(O)R. sub. 7), wherein R. sub. 7 is (C. sub. 1 -C. sub. 4)alkyl, (C. sub. 6 -C. sub. 2)aryl or N(X). sub. 2, wherein each X is H or (C. sub. 1 -C. sub. 4)alkyl, and the pharmaceutically-acceptable salts thereof.

5439936, Aug 8, 1995

Feb 9, 1993

8/015179

Michael J. Kelner - La Jolla CA
Trevor C. McMorris - La Jolla CA
Raymond Taetle - Tucson AZ

The Regents of the University of California - Oakland CA

A61K 3122, A61K 3112

514546

A therapeutic method is provided to inhibit tumor cell growth in a subject in need of said therapy is provided, comprising parenterally administering a therapeutic amount of a compound in a pharmaceutically acceptable carrier, wherein said compound has the structure: ##STR1## wherein R is selected from the group consisting of: ##STR2## and wherein said tumor cell is sensitive to inhibition by said compound and is selected from the group consisting of a myeloid leukemia cell, a T-cell leukemia cell, a lung carcinoma cell, an ovarian carcinoma cell, and a breast carcinoma cell.

5523490, Jun 4, 1996

Nov 1, 1994

8/332940

Michael J. Kelner - La Jolla CA
Trevor C. McMorris - La Jolla CA
Raymond Taetle - Tucson AZ

The Regents of the University of California - Oakland CA

C07C21100

568374

A compound to inhibit tumor cell growth in a subject in need of said therapy is provided, wherein said compound has the structure: ##STR1## wherein R is selected from the group consisting of: ##STR2## Tumor cells sensitive to inhibition by said compound are selected from the group consisting of a myeloid leukemia cell, a T-cell leukemia cell, a lung carcinoma cell, an ovarian carcinoma cell, and a breast carcinoma cell.